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Abstract
Background: The ability to site-specifically conjugate a protein to a payload of interest (e.g., a fluorophore, small
molecule pharmacophore, oligonucleotide, or other protein) has found widespread application in basic research
and drug development. For example, antibody-drug conjugates represent a class of biotherapeutics that couple
the targeting specificity of an antibody with the chemotherapeutic potency of a small molecule drug. While first
generation antibody-drug conjugates (ADCs) used random conjugation approaches, next-generation ADCs are
employing site-specific conjugation. A facile way to generate site-specific protein conjugates is via the aldehyde
tag technology, where a five amino acid consensus sequence (CXPXR) is genetically encoded into the protein
of interest at the desired location. During protein expression, the Cys residue within this consensus sequence
can be recognized by ectopically-expressed formylglycine generating enzyme (FGE), which converts the Cys to a
formylglycine (fGly) residue. The latter bears an aldehyde functional group that serves as a chemical handle for
subsequent conjugation.
Results: The yield of Cys conversion to fGly during protein production can be variable and is highly dependent on
culture conditions. We set out to achieve consistently high yields by modulating culture conditions to maximize
FGE activity within the cell. We recently showed that FGE is a copper-dependent oxidase that binds copper in a
stoichiometric fashion and uses it to activate oxygen, driving enzymatic turnover. Building upon that work, here we
show that by supplementing cell culture media with copper we can routinely reach high yields of highly converted
protein. We demonstrate that cells incorporate copper from the media into FGE, which results in increased specific
activity of the enzyme. The amount of copper required is compatible with large scale cell culture, as demonstrated
in fed-batch cell cultures with antibody titers of 5 g · L−1, specific cellular production rates of 75 pg · cell−1 · d−1, and
fGly conversion yields of 95–98 %.
Conclusions: We describe a process with a high yield of site-specific formylglycine (fGly) generation during
monoclonal antibody production in CHO cells. The conversion of Cys to fGly depends upon the activity of FGE,
which can be ensured by supplementing the culture media with 50 uM copper(II) sulfate.
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Background
Formylglycine (fGly) is a cotranslational modification of
cysteine that can be used as a bioorthogonal chemical
handle for site-specific protein conjugation [1, 2]. fGly is
installed on a protein in the endoplasmic reticulum (ER)
through the action of formylglycine-generating enzyme
(FGE). FGE binds to its consensus sequence, CXPXR,
where X represents any amino acid except proline, and
catalyzes the oxidation of the Cys thiol to an fGly alde-
hyde (Fig. 1). The endogenous substrates for FGE are
sulfatase enzymes that use the fGly residue in their cata-
lytic cycle. However, FGE can also recognize non-native
substrate proteins bearing the FGE consensus sequence
[3]. This substrate flexibility has been exploited by
protein engineers in order to site-specifically modify
proteins with a bioorthogonal chemical handle. Using
standard molecular biology techniques, the FGE consen-
sus sequence—or “aldehyde tag”—can be inserted at a
desired location within a protein of interest. Coexpres-
sion of FGE with the aldehyde-tagged protein leads to
fGly-containing proteins (Fig. 1). Although proving to be
a useful tool [4–10], the yield of Cys to fGly conversion
on these recombinant proteins has been inconsistent.
For example, when aldehyde-tagged Fc proteins were
expressed in CHO cells—which express low levels of
hamster FGE—in the absence of exogenous FGE overex-
pression, the proportion of fGly to Cys in the final prod-
uct was 28–67 % [3]. The reported fGly yield improved
somewhat when FGE was overexpressed in the cells via
transient (45–91 %) or stable (62–77 %) transfection [1].
We use the aldehyde tag in combination with pro-
prietary aldehyde-reactive chemistries as a site-specific
conjugation platform called SMARTag™. Our technol-
ogy aims to enable the large-scale production and
commercialization of aldehyde-tagged (and conju-
gated) proteins, such as antibody-drug conjugates [9,
10]. To this end, we sought to reduce the variability in
fGly yield and push the protein yields as high as
possible in order to achieve maximum production effi-
ciency. We recently determined that the catalytic mechan-
ism employed by FGE requires a copper cofactor [11].
With that in mind, we explored supplementing cell cultures
with copper, and found that addition of 50 μM copper(II)
sulfate to the culture media was sufficient to significantly
increase fGly yields, even under manufacturing conditions
using fed-batch cell cultures with antibody titers of 5 g · L−1
and in a 100 L bioreactor run reaching 2.9 g · L−1.
Results and discussion
Intracellular FGE levels do not correlate with Cys to fGly
conversion
As a first step to address the variability of fGly conver-
sion levels, we considered that differences in intracellu-
lar FGE levels might affect conversion yields. Wild-type
human FGE is partially retained in the ER through inter-
actions of its N-terminal region (called the N-terminal
extension, NTE) with endoplasmic reticulum resident
protein 44 (ERp44) [12]. This interaction can be abro-
gated by furin-mediated proteolytic cleavage at an in-
ternal site, allowing the remaining catalytically-active
core enzyme to be secreted [11]. With this in mind, we
took two approaches towards retaining FGE inside the
cell. One was to delete the furin cleavage site, leaving
FGE intact and able to retain its interactions with
ERp44. The other was to incorporate an alternative ER-
retention signal—a KDEL sequence—at FGE’s C-terminus.
In some iterations, both modifications were included in
the same construct.
Fig. 1 Formylglycine-generating enzyme (FGE) converts the Cys found within in its consensus sequence to an fGly residue. The FGE consensus
sequence, CXPXR, where X is any residue except proline, is genetically encoded into a desired location within the target protein of interest, e.g.,
an antibody. Vectors encoding this “aldehyde-tagged” protein and the FGE enzyme are introduced into a cell; then, during protein production
FGE cotranslationally modifies the Cys within the CXPXR sequence, removing the thiol group and replacing it with an aldehyde, resulting in an
overall conversion from a Cys to a formylglycine (fGly) residue. The aldehyde group within the fGly serves as a chemical handle that can be used
for downstream site-specific bioconjugation
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Plasmids encoding these various forms of FGE, includ-
ing wild-type, furin site-deleted (DFur), +KDEL, and
DFur + KDEL, were used to make CHO-S clonal cell
lines stably expressing the FGE isoforms under the con-
trol of the human EF1α promoter. Then, from these
lines we selected FGE clones with varying levels of intra-
cellular FGE as determined by flow cytometry and
enzyme-linked immunosorbent assay (ELISA)-based ex-
periments (Additional file 1: Figure S1). Next, we tested
the efficiency of conversion on transiently-expressed
antibodies in these clones. Furthermore, we also gener-
ated stable pools of antibody-expressing cells by trans-
fecting these FGE clones. Together, the transient
transfections and stable pools covered two antibody
backbones and two aldehyde tags placed at different
locations—at the C-terminus of the heavy chain (CT)
and in the hinge region. Although the antibody titers
from these cultures were low, conversion analyses dem-
onstrated that there was no correlation between conver-
sion efficiency and intracellular FGE levels, or forms of
FGE, under these conditions (Table 1).
fGly conversion is affected by cell culture media and time
in culture
From this work, we selected a stable CHO-S clone ex-
pressing FGE + KDEL and CT-tagged antibody 2 (clone
101, Table 1) to test the effect of media on fGly yield. As
a starting point, we cultured the cells in either CD Forti-
CHO™ or PF-CHO™ LS, and measured titer, viability, cell
density, and conversion to fGly. We observed that the
media had a pronounced effect on the fGly yield (Fig. 2).
Cells cultured in PF-CHO™ LS yielded highly converted
antibody throughout the production run with 98 % fGly
at day 7 and 86 % fGly at day 14. By contrast, cells cul-
tured in CD FortiCHO™ produced antibody that con-
tained a decreasing amount of fGly as time in culture
proceeded. While antibody from this culture contained
70 % fGly at day 5, by day 11 the proportion of fGly had
dropped to 20 %. Meanwhile, the viability of the cells
over time was similar under both conditions, but the ti-
ters were approximately two-fold higher in the PF-
CHO™ LS media, and cell density was two- to three-fold
higher in the CD FortiCHO™ media (Table 2).
Addition of copper(II) sulfate to cell culture media
increases conversion yields
The dependence of fGly yields on cell culture conditions
suggested that a media component might be limiting.
We recently determined that the catalytic mechanism
employed by FGE requires a copper cofactor [11].
Therefore, the cells require a stoichiometric amount of
copper to match FGE enzyme levels in order to ensure
FGE activity. The disparity observed in the conversion
levels of antibodies produced in PF-CHO™ LS and CD
Table 1 FGE form does not correlate with conversion yield
Transient Ab 1, CH-CT Transient Ab 2, Hinge Stable Ab 1, CH-CT Stable Ab 2, CH-CT Stable Ab 2, Hinge











395-12 WT Low 11.8 96 % 10.5 81 % ND ND 2.1 99 % 1.6 99 %
395-12 WT Low 3.7 90 % 6.6 69 % ND ND 1.6 98 % ND ND
408-102 Fur + KDEL High 11.5 95 % 9.9 81 % ND ND 1.1 98 % 1.2 90 %
409-107 Fur + KDEL Low 1.4 83 % 6.8 69 % 2 97 % 1.1 97 % ND ND
407-118 +KDEL High 11.8 97 % ND ND 4.7 97 % 0.9 98 % 1.3 99 %
406-127 Fur Med 1.9 80 % 7.4 54 % 7.8 92 % 1.5 94 % ND ND
409-35 Fur + KDEL Med ND ND 6.5 68 % 1.7 92 % 2 98 % ND ND
aΔFur, deleted furin cleavage site






















Fig. 2 fGly conversion is affected by cell culture media and time in
culture. A CHO-S clone (clone 101) stably expressing FGE + KDEL and
CT-tagged antibody was cultured in PF-CHO™ or FortiCHO™, fed
with 10 % Efficient Feed C on Days 3, 5, and 7, and supplemented
with 3 g/L glucose when levels dropped below 3 g/L. Samples of
media were taken at the indicated days (harvest was at day 11 and
day 14 for FortiCHO™ and PF-CHO™ cultures, respectively). Titers
(indicated by the numbers atop bars, mg/L) were assessed by ELISA,
and conversion was determined by mass spectrometry. Representative
data are shown (n =2 experiments)
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FortiCHO™ media could reflect differing amounts of
copper contained in those proprietary media (for which
the components are not disclosed). Furthermore, the
decreasing conversion yields observed over time in cul-
ture—most strongly exemplified in the CD FortiCHO™
cultures—may reflect depletion of copper in the media
through cell growth and metabolism. In order to test
this theory, we cultured clone 101 in CD FortiCHO™
media +/- supplementation with 5, 20, or 50 μM cop-
per(II) sulfate added on day 0. Media was harvested on
day 10 and antibodies were analyzed for conversion
(Fig. 3a). The results showed that addition of 5 μM or
more copper(II) sulfate led to fGly yields of ≥ 96 % as
compared to a 77 % yield in cells that were not supple-
mented with copper.
In order to test the dependence of timing on this ef-
fect, we cultured clone 101 in CD FortiCHO™ media +/-
supplementation with 50 μM copper(II) sulfate added on
day 3 or day 5. Media was harvested on day 12 and anti-
bodies were analyzed for conversion (Fig. 3b). The re-
sults showed that addition of copper at either time point
gave similar results as addition at day 0; namely, fGly
yields ≥ 95 % as compared to a 58 % yield in cells that
were not supplemented with copper.
In order to test the specificity of the observed copper
effect on fGly yields, we tried substituting various other
metal ions that are common enzyme cofactors, including
iron sulfate, magnesium chloride, and zinc chloride
(Additional file 1: Figure S2). None of these metals im-
proved the fGly yield over media alone. This result was
consistent with our observations of purified FGE, which
showed that only copper, but not these other cofactors,
could increase the enzyme’s specific activity [11].
Addition of copper(II) sulfate to cell culture media results
in FGE copper loading and holoenzyme formation
Transport and delivery of copper is a tightly regulated
process in eukaryotes [13]. By one estimate, there is no
unbound (free) intracellular copper [14]. Therefore, the
addition of copper to culture media did not guarantee
that it would be incorporated into the FGE enzyme. To
test this, we prepared a variant of human FGE
containing a His6 affinity tag (H6-Hs-FGE). Transient
cotransfection of vectors containing H6-Hs-FGE and the
CT-tagged antibody was performed in Expi293™ cells +/-
supplementation of 50 μM copper(II) sulfate in the cell
culture media. After 4 days in culture, the cells were
washed to remove excess media (and free copper), lysed,
and H6-Hs-FGE was purified from the cell lysate using
metal affinity chromatography (Fig. 4a). After purifica-
tion, H6-Hs-FGE was assayed for copper content and
specific activity (Fig. 4b and c). Inductively coupled
plasma mass spectrometry (ICP-MS) analysis of the
purified enzymes demonstrated that the enzyme purified
from copper-treated cells contained more copper
(0.74 mol/FGE, 74 % holo enzyme) as compared to the
enzyme purified from untreated cells (0.03 mol/FGE,
Table 2 Conversion to fGly is highly dependent on cell culture
conditions
Media Culture day Density
(million/mL)
Viability Titer (mg/L) Conversion
PF-CHO Day 7 2.8 90 % 29.4 98 %
Day 10 4.5 95 % 49.7 96 %
Day 14 3.4 80 % 101.7 86 %
FortiCHO Day 5 >10 99 % 4.4 70 %
Day 7 17 99 % 12.6 42 %
Day 10 10 80 % 33.2 36 %
Day 11 5.3 66 % 48.7 20 %
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Fig. 3 fGly conversion proceeds efficiently in cells cultured in the presence of 5–50 μM copper(II) sulfate. CHO-S clone 101 stably expressing
FGE + KDEL and CT-tagged antibody was cultured in FortiCHO™ +/- the indicated concentrations of copper(II) sulfate added on day 0 (a), or with
50 μM copper(II) sulfate added on days 3 or 5 (b). Cultures were fed with 10 % Efficient Feed C on Days 3, 5, and 7. Media was harvested at
day 10 (a) or day 12 (b); titers (indicated by the numbers atop bars, mg/L) were assessed by ELISA, and conversion was determined by mass
spectrometry. n = 7 experiments for 0 and 50 μM copper(II) sulfate added on day 0; other time points and copper(II) sulfate concentrations were
tested once
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3.0 % holo enzyme). Accordingly, we found that the FGE
isolated from cells grown in copper-containing media
was significantly more active [1604 ± 196 picokatal (pkat)
per mg] than that isolated from untreated cells (190 ±
116 pkat/mg). Finally, we measured the fGly content in
the purified antibody, which also correlated with the
presence (74 % fGly) or absence (19 % fGly) of the cop-
per supplement (Fig. 4d). Together, these data demon-
strated that addition of copper(II) sulfate to the cell
culture media was sufficient to provide FGE with the re-
quired copper cofactor, which then allowed the enzyme
to efficiently convert Cys to fGly during protein produc-
tion. Interestingly, this copper loading does not occur
efficiently when FGE is produced in E. coli [11]. Cop-
per supplementation of bacterial cultures does result
in a modest improvement in holoenzyme formation
(data not shown), but to a much lesser extent than
that observed in mammalian cells. Insect cells cul-
tures are also efficient at holoenyzme formation [11].
High conversion and titers are observed in transiently
transfected cultures supplemented with copper(II) sulfate
Because the previous experiments were conducted using
stable FGE clones, next we tested whether conversion
could proceed efficiently in a fully-transient expression
system (Fig. 5). For this purpose, we used Expi293F™
cells cotransfected with three vectors, one each encoding
FGE, the antibody light chain, and the antibody heavy
chain. Furthermore, we asked whether FGE could con-
vert aldehyde tags installed at any of several locations on
the same antibody, or at the same location on multiple
human IgG1 antibodies. With respect to tag placement,
we tested three variants of an antibody with the alde-
hyde tag installed in either the CH1, the hinge, or at the
CT. The transient titers of these antibodies ranged from
157 to 578 mg/L (Fig. 5a), and the conversion of Cys to
fGly was consistently high (88–97 %, Fig. 5b). With re-
spect to antibodies with different variable regions, the
installation of the aldehyde tag at the same site (CT)
across three different IgG1 antibodies resulted in similar
titers and high conversion (Fig. 5c and d).
GPEx® system-derived clones stably expressing
both FGE and aldehyde-tagged antibody yield
high titers and high conversion
Bolstered by these positive results in transient cultures,
we next tested stable cell lines that could eventually be
expanded into a manufacturing process. A retrovector
transduction (GPEx® technology; [15]) of CHO cells was
performed to incorporate human FGE into cellular
DNA, generating stable pools from which clones were
selected. Stable expression of human FGE in the clones
was confirmed by flow cytometry. Then, the FGE clones
were transduced to generate stable pools of antibody ex-
pressing cells. These cells were tested for antibody titer
and fGly conversion during culture in three common
media types, for which the copper content is not dis-
closed: PF-CHO™ LS, CD OptiCHO™, and HyCell™ (Fig. 6).
Without copper(II) sulfate supplementation, we observed
good titers, but variable conversion yields in antibodies
produced in these media. By contrast, addition of copper
to the cultures led to consistently high fGly content
without decreasing titers. In the case of PF-CHO™ LS, the
yield of fGly in the purified antibody increased from 74 ±
4 % (n = 3) to 94 ± 2 % (n = 3).
Subcloning of these stable pools by limiting dilution
afforded cell lines that produced high amounts of pro-
tein (4.2 ± 0.9 g/L, n = 5) in fed batch shake flask cul-
tures (Fig. 6c). More importantly, the conversion yield
remained extremely high (98 ± 1 %, n = 5) even with the
A B C D
Fig. 4 FGE purified from copper(II) sulfate-supplemented cells contains copper and has enhanced specific activity. A gene encoding FGE
containing a His6 affinity tag was cotransfected with CT-tagged antibody into Expi293™ cells. Cells were cultured +/- supplementation
with 50 μM copper(II) sulfate. On day 4, antibody was harvested. Then, the cells were washed to remove excess media (and free copper),
lysed, and H6-Hs-FGE was purified from the cell lysate using metal affinity chromatography. Purified FGE was analyzed by reducing and
non-reducing SDS-PAGE (a). Then, the purified H6-Hs-FGE samples were assayed for copper content—by ICP-MS (b)—and for specific
activity—via an HPLC-based assay on a peptide substrate (c). Conversion of the antibody was determined by mass spectrometry (d). The
experiment was repeated four times with similar results; error bars in C represent standard deviation (n = 4). ICP-MS copper analysis (b)
and conversion analysis of the cotransfected antibody were performed once
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increased titers and productivity (Fig. 6d). We also gen-
erated clonal cell lines producing antibody containing
two aldehyde tag sites per heavy chain (CH1 and CT, or
“double tag”), resulting in four fGly sites per antibody.
Doubling the number of sites was well-tolerated by the
FGE-producing cell lines. For the top performing
doubly-tagged clones, the yields of fGly were 93.2 % ±
1.9 in the CH1 and 97.4 % ± 0.5 at the CT (n = 5); the
antibody titers were 1.9 ± 0.3 g/L (n = 5). The clonal
cell line productions of singly- and doubly-tagged
antbodies were successfully scaled to 2 L bioreactors
(Fig. 6c and d). The highest antibody-producing clone,
with a titer of 5.2 g/L, had a specific productivity





Fig. 5 Aldehyde tag conversion is independent of tag location and antibody type. The aldehyde tag was incorporated at various positions across
an antibody heavy chain—at the CH1, hinge, or heavy chain C-terminus (CH-CT). Cotransfection of vectors encoding FGE and the relevant heavy
and lights chains in Expi293™ cells enabled transient production of fGly-containing antibodies in good titer (a) and with high conversion (b). By
comparison, when untagged antibody was expressed following the same procedure, the titer was 223 mg/L. Installation of the aldehyde tag at
the CH-CT of three different IgG1-type antibodies followed by coexpression with FGE in Expi293™ cells resulted in the same high titers (c) and





Fig. 6 High fGly conversion yields can be obtained from stably transduced cell lines under high titer cell culture conditions. Stable transduction
of DNA encoding FGE, antibody light chain, and antibody heavy chain bearing one (CT only) or two (CH1 and CT) aldehyde tags was performed
with viral retrovector transduction into CHO cells (GPEx® technology). The resulting stable pools were cultured in three types of media +/-
supplementation with copper(II) sulfate (n = 3). Titers (a) and fGly conversion (b) of CT-tagged antibodies were assessed. Then, the stable pools
were cloned by limiting dilution and clone performance was assessed in fed batch cultures (c and d; shake flask, n = 5 clones; bioreactor, n = 3
clones single tag, n = 1 clone double tag). The top performing stable single-tagged clonal cell line produced antibody in very high titer (5.2 g/L)
with 98 % conversion of Cys to fGly (c and d). The specific productivity (75 pg/cell/d) of this top clone demonstrates the capabilities of the GPEx®
technology for efficient production of highly converted antibody. The generation of fGly in single- and doubly-tagged antibodies scaled successfully to
bioreactors (2 L cultures; c and d). Error bars indicate standard deviation
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and processes are scalable for development of clinical
and commercial products, a 100 L production run
was performed. As expected the results were similar
to the 2 L production with titers reaching 2.9 g/L,
specific productivity of 43 pg/cell/d, and fGly conver-
sion yields of 96.4 % (Fig. 7).
Conclusions
The incorporation of fGly has been leveraged for the
transport and display of a wide range of payloads, in-
cluding DNA for protein scaffolding [4]; chromophores
for probing protein dynamics [5]; anchors for solid sub-
strates [6]; immobilization of viruses [7] and enzymes
[8]; and the site-specific attachment of cytotoxic drugs
for the generation of antibody–drug conjugates (ADCs).
With site-specific conjugation, it is now possible to build
structure activity relationships for ADCs that correlate
payload placement on the antibody with efficacy, pharma-
cokinetics, and conjugate stability [9, 10, 16].
In an effort to scale up production of fGly-containing
antibody for preclinical evaluation of next-generation
ADCs, we designed a method to generate a high yield of
this modification during antibody production. Our re-
sults highlight the robust generation of fGly by FGE in
vivo. The enzyme is able to maintain a rate of turnover
that matches antibody production for the duration of
cell culture as long as it has access to sufficient amounts
of copper. Perhaps most importantly, the addition of 50
μM copper(II) sulfate to the media has no obvious dele-
terious effects on cell growth, cell density, protein titer,
or culture duration. However, considering what is known
about the impact of copper on antibody quality, includ-
ing the production of basic variants [17], we plan to
continue to refine the copper requirements during anti-
body production. As a first step towards establishing re-
producible conversion in the context of a high titer
antibody production, the simple solution outlined herein
enables the generation of antibodies containing aldehyde
tags in a process that is compatible with industrial scale
production.
Methods
DNA construction of pEF1α-Hs-FGE variants
A pcDNA™3.1 vector encoding for wild-type human
FGE (wt-Hs-FGE) was available from a previous study
[3]. Hs-FGE UniProt accession: Q8NBK3; PDB 1Y1E.
The FGE gene was amplified by PCR using a primer en-
coding for the kozak consensus sequence and cloned
into pcDNA™3.1(-) hygro to generate pcDNA™3.1-hygro-
kozak-FGE flanked by NruI and NheI restriction sites.
Subsequently, the EF1α promoter was amplified from
the pEF1α-IRES vector (Clontech) by PCR using primers
containing NruI/NheI sites. Both the FGE vector and the
EF1α PCR product were digested with NruI and NheI
and ligated with the Rapid DNA Ligation Kit (Thermo/
Life Technologies) to generate WT pEF-FGE-hygro,
which was amplified in XL-10 gold cells (Agilent) and
purified according to the manufacturer’s instructions.
Quikchange Mutagenesis (Agilent) was used to mutate
the furin cleavage site (HRYSRE to HRYSGE) and/or
add the KDEL retention signal to the C-terminus of FGE
to generate Δfurin, +KDEL, and Δfurin + KDEL versions
of FGE.
Transfection of CHO-S cells with pEF-FGE variants and es-
tablishment of clonal cell lines
CHO-S cells were transfected with the pEF-FGE-hygro
variants described above using FreeStyle™ Max transfec-
tion reagent in OptiPro™ serum-free media following the
manufacturer’s protocol. After overnight recovery of
growth, the cells were pelleted and grown in PF-CHO™
LS (GE Healthcare) under hygromycin selection (400 μg/
mL). After 8 d of selection, the cell viability was 10 %.
Continued passaging for 14 d allowed recovery of stable




























Integral of Viable Cell Density 
Fig. 7 A GPEx® clonal cell line expressing CT-tagged antibody afforded high fGly conversion and high titers in a 100 L bioreactor production run.
Cells were cultured in HyCell™ media supplemented with 50 μM copper(II) sulfate. The protein concentration and integral of viable cell density is
shown. Cultures were terminated when viabilities were 80 %. Titers of 2.9 g/L were reached. The cells demonstrated a specific productivity of
43 pg/cell/d, and the resulting antibody had fGly conversion yields of 96.4 %
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pools to 99 + % cell viability (CHO-S-FGE-pool). Then,
stable CHO-S-FGE-pools were cloned by limiting dilution
in 96-well plates using semi-solid ClonaCell™ media
(STEMCELL Technologies). Surviving clones were ex-
panded to six well plates for selection and characterization.
The final clones were propagated in CD FortiCHO™ media
with 125 μg/mL hygromycin selection.
Transient transfection of CHO-S-FGE cells with CHCT-anti-
body and establishment of clonal cell lines
Two vectors encoding for the target antibody heavy
(HC) and light chains (LC) were generated using stand-
ard molecular biology techniques from a vector encod-
ing the pCF promoter (the CMV promoter with the
adenovirus tripartite leader). CHO-S-FGE cells express-
ing different FGE variants were transfected with the
vectors encoding HC and LC using FreeStyle™ Max
transfection reagent in OptiPro™ serum-free media fol-
lowing the manufacturer’s protocol. For transient protein
production, cells were cultured under standard condi-
tions for 5 days and antibody was harvested using
Protein A. To generate stable clonal cell lines of FGE
and antibody expressing cells, transfections were per-
formed as described, then after overnight recovery of
growth, the cells were pelleted and grown in PF-CHO™
LS® under both hygromycin (250 μg/mL) and G418
(500 μg/mL) selection. After day 6, the cell viability had
decreased to 50 %. Continued passaging under selection
for 14 days allowed recovery of the stable pools to 99 + %
cell viability (CHO-S-FGE-antibody-pool). The stable
CHO-S-FGE-antibody-pools were cloned by limiting
dilution in 96-well plates using semi-solid ClonaCell™
media (STEMCELL Technologies). Surviving clones
were expanded to six well plates for selection and
characterization. The final clones were propagated in
CD FortiCHO™ media (Thermo Fisher) with hygromy-
cin (125 μg/mL) and G418 (250 μg/mL).
Fed batch production of antibody from CHO-1
CHO-1 was used to produce antibodies under a variety
of experimental conditions, all of which included the an-
tibiotics described for CHO-1 propagation. In brief,
CHO-1 was seeded into 30–120 mL of fresh media
(typically CD FortiCHO™, PF-CHO™ LS, or HyCell™) at
0.5x106 cells/mL. Copper(II) sulfate (when used) was
added on day 0 as a 1000x stock solution in water. The
cell culture was fed with supplements on day 0, and with
glucose whenever the level was below 2 g/L.
DNA construction of His6-Hs-FGE in pcDNA3.1(-)myc-His
Wild-type H. sapiens FGE (SUMF1, NCBI 285362) was
amplified from a pcDNA 3.1 construct available from a
previous study [3]. The insert and pcDNA 3.1(-)myc-His
(Invitrogen) were digested with EcoRI and HindIII and
ligated following the manufacturer’s instructions.
Transient coexpression of His6-Hs-FGE and CHCT-antibody
The expression constructs for FGE and the antibody
heavy and light chains were introduced into Expi293F™
cells at a 1.6:2:3 ratio (FGE:HC:LC) following the manu-
facturer’s instructions. Cells were cultured in Expi293™
media with enhancers as specified by the manufacturer.
Copper(II) sulfate was added as a 1000x stock solution
on the day of transfection. The media and cells were
harvested after 4 d. Cells were removed by centrifuga-
tion. Antibodies were purified from the conditioned
medium using Protein A chromatography with MabSe-
lect SuRe™ resin (GE Healthcare).
Purification of H6-Hs-FGE from Expi293F™ cells
The Expi293F™ cell pellet was resuspended in lysis buffer
(25 mM triethanolamine, 300 mM NaCl, 1 % triton X-
100, protease inhibitors). This solution was loaded onto
Ni-NTA superflow (Qiagen). The resin was washed with
10 column volumes of wash buffer (25 mM triethanola-
mine [TEAM], 250 mM NaCl, 5 mM calcium acetate,
10 mM imidazole, pH 8). The enzyme was then removed
from the column with elution buffer (25 mM TEAM,
5 mM calcium acetate, 300 mM imidazole, pH 8). Frac-
tions containing protein as determined by protein assay
(Bio-Rad) were pooled and loaded onto a Sephadex® G-
25 column equilibrated with assay buffer, eluted, and
concentrated by centrifugal ultrafiltration.
DNA construction and cloning for retrovector production
The FGE gene sequence (SUMF1, NCBI 285362) con-
taining a C-terminal KDEL sequence was cloned into
the Catalent’s GPEx® expression vector containing the
Neomycin-resistant gene. The heavy and light chain
antibody gene sequences were codon optimized for
CHO cell expression and a proprietary signal peptide se-
quence was added to the coding sequences. Both DNA
sequences of antibody heavy and light chains were
cloned into Catalent’s GPEx® expression vectors.
Retrovector production for stable transduction
The expression constructs encoding FGE, LC, or HC
were introduced into the 293 cells. These cells originate
from a fully characterized HEK 293 cell line that constitu-
tively produces the MLV gag, pro, and pol. This replication
incompetent system produces high titer retrovector that is
concentrated by ultracentrifugation and used for cell
transductions.
Transduction of GCHO Cells with Retrovector
The GCHO FGE cell line was made by performing three
rounds of transduction (multiplicity of > 1000
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retrovector particles/cell) of the GPEx® Chinese Hamster
Ovary (GCHO) parental cell line with retrovector made
from the gene construct developed to express FGE. The
GCHO antibody cell line was made by performing mul-
tiple rounds of transduction (multiplicity of >1000 retro-
vector particles/cell) of the GPEx® Chinese Hamster
Ovary (GCHO) FGE parental cell line with retrovector
made from the gene construct developed to express the
antibody LC and HC. Five independent transductions
were performed: two LC and three HC.
Fed batch production of antibody from the pooled
population of cells
Post-transduction, the pooled population of GCHO-
Antibody cells was scaled up for productivity in fed
batch studies in duplicate 2.8 L shake flasks. Each shake
flask was seeded with 300,000 viable cells per mL in a
1400 mL working volume of either PF-CHO™ LS, CD
OptiCHO™, or HyCell™ media and incubated in a hu-
midified (70–80 %) shaking incubator at 90 rpm with
5 % CO2 at 37 °C. Cultures were fed based on viable cell
density and glucose levels. Cultures were terminated
when viabilities were ≤ 50 %. Antibody expression was
determined by Protein A HPLC using a generic IgG
standard.
Establishment of clonal cell lines from transduced GCHO
cells
Limited clonal dilution in 96 well plates was performed
on the pooled population of GCHO-Antibody cells.
From over 400 clones, the top 20 clones based on pro-
tein titer (ELISA using a generic IgG standard) were
expanded and analyzed in an enhanced fed batch prod-
uctivity study.
Fed batch production of antibody from clonal cell lines
(shake flask)
The top twenty clones were selected based on antibody
titer from a 96 well plate. The selected clonal cell lines
were tested for productivity in an enhanced fed batch
overgrowth study. For each clone, duplicate T75 shake
flasks were seeded with 300,000 viable cells per mL in
60 mL working volume of HyClone™ HyCell™ media (GE
Healthcare) and incubated in a humidified (70–80 %)
shaking incubator at 120 rpm with 5 % CO2 at an initial
temperature of 37 °C. Cultures were fed on designated
days. A temperature shift was also performed on Day 4.
Cultures were terminated when viabilities were ≤ 50 %.
Antibody expression was determined by Protein A
HPLC using a generic IgG standard. After production,
antibodies were purified from the conditioned medium
using Protein A chromatography with MabSelect SuRe™
resin (GE Healthcare).
Fed batch production of antibody from clonal cell lines
(bioreactor)
The clonal cell lines were tested for productivity in an
enhanced fed batch overgrowth study in 2 L bioreactors.
For each clonal cell line a single 2 L Sartorius/Braun
double-walled glass vessel was seeded with 300,000 vi-
able cells per mL in 1400 mL working volume of
HyCell™ media (HyClone™). The operating parameters of
2 L bioreactors, controlled by Finesse units, were as fol-
lows: initial temperature of 37 °C, dissolved oxygen
(DO) of 50 % and pH 7.0 (upper deadband of 0.60, lower
deadband of 0.20). Cultures were fed on designated days.
A temperature shift was also performed on Day 5. Cul-
tures were terminated when viabilities were ≤ 80 %. Anti-
body expression was determined by Protein A HPLC
using a generic IgG standard. After production, anti-
bodies were purified from the conditioned medium
using Protein A chromatography with MabSelect SuRe™
resin (GE Healthcare).
Flow cytometry
For each sample, 1 million cells were centrifuged at
300 × g. The medium was removed by aspiration and the
cells were washed with phosphate buffered saline (PBS) +
1 % bovine serum albumin (BSA) and transferred to a 96
well plate. The PBS was removed by aspiration, and the
cells were fixed with 100 μl ice cold methanol on ice for
15 min. The cells were again centrifuged at 300 × g and
gently washed with ice cold PBS + 1 % BSA. The cells were
then gently resuspended in 100 μl of the primary antibody
solution, a 1:100 dilution of mouse anti-human/mouse
SUMF1 IgG (R&D Systems) in PBS + 1 % BSA. The cells
were then incubated for 1 h at RT with shaking. After, the
cells were washed twice with PBS + 1 % BSA, and then re-
suspended in the secondary Ab solution, a 1:100 dilution
of phycoerythrin-conjugated anti-mouse IgG in PBS + 1 %
BSA. The cells were then incubated for 1 h at RT with
shaking in the dark. Finally, the cells were washed twice
with PBS + 1 % BSA and analyzed on a BD FACSCanto™
Flow Cytometer.
Quantification of fGly content in an antibody
Determination of fGly content was performed using
methods previously described [11]. In brief, fGly content
was determined by liquid chromatography-multiple re-
action monitoring/mass spectrometry (LC-MRM/MS)
after antibody reduction with DTT, followed by prote-
olysis and chemical modification of Cys (iodoacetamide)
or fGly (methoxylamine). Mass Spectrometry data were
collected on a 4000 QTRAP® mass spectrometer (AB
Sciex) with an 1100 series HPLC (Agilent). Chromatog-
raphy was performed on a Jupiter™ 150 × 1.0 mm C18
column (Phenomenex) enclosed in a butterfly column
heater set to 65 °C with a PST-CHC controller (Phoenix
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S&T). Calculation of LC-MRM/MS transition masses
and integration of the resulting data was performed with
Skyline 2.6 [18]. The quantity of each species was inte-
grated and fractions of the total were calculated.
Quantification of FGE specific activity
The method for determining FGE specific activity was
previously reported [11]; in brief, a synthetic peptide, en-
coding the consensus sequence for FGE was used in
vitro as a substrate for the enzyme. The peptide sub-
strate was made by New England Peptide, Inc. on solid
phase and purified to ≥95 %. After treatment of the pep-
tide with FGE, the conversion of Cys to fGly was mea-
sured by separating the two forms of the peptide by
reversed-phase high performance liquid chromatography
(RP-HPLC) and integrating the peak areas for each spe-
cies. RP-HPLC was performed on an 1100/1200 series
instrument (Agilent Technologies) controlled with Agi-
lent OpenLAB CDS Chemstation Edition. The instru-
ment consisted of an in-line solvent degasser, analytical
quaternary pump, vial auotsampler, thermostatted col-
umn compartment, and diode array detector. Chroma-
tography was achieved on an Aeris™ core-shell 250 ×
2.1 mm XB-C18 Widepore column (Phenomenex, Inc.).
Absorption spectroscopy
UV and visible absorption spectra were recorded on a
NanoDrop™ 2000 (Thermo Scientific) spectrophotometer
with manufacturer-supplied software. Spectrometers were
calibrated with NIST-traceable potassium dichromate
standards for photometric accuracy (Starna Scientific).
ICP-MS
Inductively-coupled plasma mass spectrometry (ICP-
MS) was performed by the Catalent Center for Excel-
lence in Analytical Services (Morrisville, NC). The ratio
of copper was calculated as a mol ratio based upon pro-
tein concentrations measured from 280 nm absorption
intensity of enzyme stock solutions.
Computing and software
All instrument data collection workstations were oper-
ated with PCs and instrument control software as pro-
vided by the manufacturers. Linear and nonlinear
regression was performed using Prism® 6.0e (GraphPad).
Integration of HPLC chromatograms was performed
using OpenLAB CDS Chemstation Edition (Agilent).
Calculation of LC-MRM/MS transition masses and inte-
gration of the resulting data was performed with Skyline
2.6 (MacCoss Lab, University of Washington). Statistical
calculations were performed with Microsoft Excel.
Statistics
When displayed on bar graphs, measurements of uncer-
tainty represent the standard deviation. Area under the
curve (AUC) for HPLC runs was calculated by the
Chemstation software using the “new exponential” algo-
rithm and setting slope sensitivity of 1 mAU. Kinetic pa-
rameters were determined from nonlinear regression of






Additional file 1: Table S1. FGE isolated from Expi293™ cell culture
contains both copper and calcium as measured by ICP-MS. Figure S1.
Intracellular FGE levels can be determined by flow cytometry or ELISA.
Figure S2. The effect of copper(II) sulfate addition on conversion is not
replicated by the addition of other metal cofactors. (DOCX 641 kb)
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